DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,742,922,168 | -4.0% | 19,116,972 | -7.1% | 0.48% | -1.0% |
| Q2 2023 | $4,938,703,368 | -4.3% | 20,577,925 | +0.5% | 0.49% | -11.9% |
| Q1 2023 | $5,160,945,693 | -2.2% | 20,476,689 | +3.0% | 0.55% | -7.8% |
| Q4 2022 | $5,278,696,827 | +20.9% | 19,888,087 | +17.7% | 0.60% | +0.8% |
| Q3 2022 | $4,365,162,000 | +1.6% | 16,900,235 | -0.3% | 0.60% | +6.6% |
| Q2 2022 | $4,295,773,000 | +8.4% | 16,944,511 | +25.4% | 0.56% | +4.3% |
| Q1 2022 | $3,963,797,000 | -3.4% | 13,513,088 | +8.4% | 0.54% | +5.7% |
| Q4 2021 | $4,101,736,000 | -6.2% | 12,466,903 | -13.2% | 0.51% | -14.1% |
| Q3 2021 | $4,372,479,000 | +18.7% | 14,362,364 | +4.6% | 0.59% | +21.2% |
| Q2 2021 | $3,683,781,000 | +19.7% | 13,727,018 | +0.4% | 0.49% | +7.5% |
| Q1 2021 | $3,078,328,000 | +1.5% | 13,676,592 | +0.2% | 0.45% | -3.4% |
| Q4 2020 | $3,031,603,000 | +8.7% | 13,647,267 | +5.4% | 0.47% | -13.2% |
| Q3 2020 | $2,788,059,000 | +25.1% | 12,947,840 | +2.7% | 0.54% | +9.3% |
| Q2 2020 | $2,229,092,000 | +17.3% | 12,605,840 | -8.2% | 0.49% | -4.5% |
| Q1 2020 | $1,899,733,000 | -11.3% | 13,725,405 | -1.7% | 0.52% | +3.6% |
| Q4 2019 | $2,142,835,000 | +9.6% | 13,961,650 | +3.1% | 0.50% | -3.9% |
| Q3 2019 | $1,955,013,000 | +0.8% | 13,536,068 | -0.3% | 0.52% | +0.4% |
| Q2 2019 | $1,940,199,000 | +5.0% | 13,575,413 | -3.0% | 0.52% | -1.3% |
| Q1 2019 | $1,847,860,000 | +23.5% | 13,996,820 | -3.6% | 0.52% | +16.7% |
| Q4 2018 | $1,496,711,000 | -4.7% | 14,514,276 | +0.4% | 0.45% | +14.0% |
| Q3 2018 | $1,570,824,000 | +4.1% | 14,456,310 | -5.5% | 0.39% | -3.7% |
| Q2 2018 | $1,509,237,000 | +12.0% | 15,294,250 | +11.1% | 0.41% | +9.1% |
| Q1 2018 | $1,347,649,000 | +27.7% | 13,764,158 | +21.1% | 0.37% | +29.4% |
| Q4 2017 | $1,055,181,000 | +21.5% | 11,368,056 | +12.3% | 0.29% | +11.2% |
| Q3 2017 | $868,400,000 | +47.4% | 10,123,583 | +45.0% | 0.26% | +46.1% |
| Q2 2017 | $589,285,000 | -54.9% | 6,982,877 | -54.3% | 0.18% | -11.4% |
| Q1 2017 | $1,306,774,000 | +11.6% | 15,278,514 | +1.6% | 0.20% | +4.7% |
| Q4 2016 | $1,170,836,000 | +97.6% | 15,041,568 | +99.0% | 0.19% | -5.0% |
| Q3 2016 | $592,483,000 | +13.6% | 7,558,118 | +46.3% | 0.20% | +7.4% |
| Q2 2016 | $521,760,000 | +18.3% | 5,165,940 | +11.1% | 0.19% | +10.6% |
| Q1 2016 | $440,986,000 | +10.4% | 4,648,802 | +8.1% | 0.17% | +17.2% |
| Q4 2015 | $399,282,000 | +21.7% | 4,298,892 | +11.6% | 0.14% | +19.8% |
| Q3 2015 | $328,197,000 | +4.3% | 3,851,626 | +4.7% | 0.12% | +11.0% |
| Q2 2015 | $314,746,000 | -5.6% | 3,677,373 | -6.3% | 0.11% | -11.4% |
| Q1 2015 | $333,335,000 | -45.7% | 3,926,216 | -45.1% | 0.12% | -45.1% |
| Q4 2014 | $613,485,000 | +26.7% | 7,157,704 | +12.4% | 0.22% | +20.4% |
| Q3 2014 | $484,016,000 | +10.3% | 6,370,304 | +14.2% | 0.19% | +8.1% |
| Q2 2014 | $438,999,000 | +19.7% | 5,576,036 | +14.0% | 0.17% | +11.7% |
| Q1 2014 | $366,902,000 | +24.3% | 4,892,045 | +28.0% | 0.15% | +22.2% |
| Q4 2013 | $295,129,000 | +51.9% | 3,822,927 | +36.4% | 0.13% | +37.0% |
| Q3 2013 | $194,299,000 | +18.9% | 2,802,941 | +8.6% | 0.09% | +12.2% |
| Q2 2013 | $163,366,000 | – | 2,580,805 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |